Scranton gives $100,000 in grants to eight veterans' service organizations
SCRANTON — An idea a decade ago for a memorial to honor the hundreds of Scranton veterans who died in wars resulted five years later in the Scranton Veterans Memorial Park at Scranton High School.
The city this year gave the memorial park a $5,000 grant for ongoing maintenance and replacement of flags.
The memorial park and seven other organizations that serve veterans received city grants totaling $100,000 to help them in various ways, including renovating buildings and providing individual assistance services, Mayor Paige Gebhardt Cognetti said Monday during an event at American Legion Connolly Post 568 in Minooka.
Scranton Mayor Paige Cognetti announces grants awarded to veterans at the American Legion Post 568 in Scranton Monday, May 19, 2025. (SEAN MCKEAG / STAFF PHOTOGRAPHER)
The funding, in the city's 2025 operating budget, continues the city's commitment to local veterans, the mayor said. The $100,000 represents an increase from the $80,000 total awarded in 2023 and $85,000 in 2024.
'As a veteran, I like to see how this program has grown over the last three or four years. Who knows what's going to happen in the next five years?' said Pat Ahern, chairman of Scranton Veterans Memorial Park during the announcement event.
'We have so many different organizations now. It's like planting a tree. It starts off small but eventually it grows,' Ahern said.
Vice commander of the American Legion Post 568 Tom Benson joins other legion members as Scranton Mayor Paige Cognetti announces grants awarded to veterans outside of the legion in Scranton Monday, May 19, 2025. (SEAN MCKEAG / STAFF PHOTOGRAPHER)
The city accepted grant applications through April. The recipients, grant amounts and other representatives of recipient organizations who spoke during the announcement event included:
• Agency for Community EmPOWERment of NEPA (ACE), 123 Wyoming Ave., $5,000 to support the Veterans Rise and Ride program that provides transportation to employment and medical appointments. 'This $5,000 was really lifesaving,' ACE Executive Director Jim Wansacz said. 'Without that grant, we would have had to shut that (ride service) down.'
• American Legion Connolly Post 568, 2929 Birney Ave., $20,000 for upgrades to the community hall to improve energy efficiency and provide ADA-compliant seating. Post Commander Sean O'Shea said the post's membership is older and raising money for building maintenance and modernization is difficult. 'We're very grateful for this' grant.
• Bread Basket of NEPA, 550 Madison Ave., $5,000 for its Veteran Food Security Support Initiative which helps Lackawanna County veterans struggling with food insecurity.
• Fight4Vets, 711 Davis St., $10,000 for a rent assistance program that combats veteran homelessness by providing emergency rent support and additional prevention services.
• Scranton Veterans Memorial Park, located at Scranton High School, 63 Munchak Way, Scranton, $5,000 to purchase flags for each Armed Forces branch and continued maintenance of the site.
• UKAVETS, 237 Railroad Ave., $10,000 for the replacement of outdated facilities.
• Valhalla Veterans Services, 2754 Jackson St., $20,000 to support Valhalla's Hope, which removes financial barriers to mental health counseling and suicide intervention services for local veterans.
• Warrior Strong, 311 Adams Ave., $25,000 to support the Resilient Warriors program, its unique comprehensive health and wellness program.
Warrior Strong President Tom Tice said support from the city allowed his organization to double its offerings and open its studio much more often to veterans and their families.
'We can really tell the community — the veteran community — is using our programs every single day,' Tice said.
American Legion Connolly Post 568, 2929 Birney Ave., Scranton, on Monday, May 19, 2025. (JIM LOCKWOOD / STAFF PHOTO)
*
American Legion Connolly Post 568, 2929 Birney Ave., Scranton, on Monday, May 19, 2025. (JIM LOCKWOOD / STAFF PHOTO)
*
Scranton Mayor Paige Cognetti announces grants awarded to veterans at the American Legion Post 568 in Scranton Monday, May 19, 2025. (SEAN MCKEAG / STAFF PHOTOGRAPHER)
*
Vice commander of the American Legion Post 568 Tom Benson joins other legion members as Scranton Mayor Paige Cognetti announces grants awarded to veterans outside of the legion in Scranton Monday, May 19, 2025. (SEAN MCKEAG / STAFF PHOTOGRAPHER)
*
American Legion Connolly Post 568, 2929 Birney Ave., Scranton, on Monday, May 19, 2025. (JIM LOCKWOOD / STAFF PHOTO)
Show Caption
1 of 4
American Legion Connolly Post 568, 2929 Birney Ave., Scranton, on Monday, May 19, 2025. (JIM LOCKWOOD / STAFF PHOTO)
Expand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
7 hours ago
- Business Upturn
BexBack Launches $50 Welcome Bonus and 100% Deposit Match to Empower Crypto Traders with 100x Leverage
By GlobeNewswire Published on June 21, 2025, 19:14 IST SINGAPORE, June 21, 2025 (GLOBE NEWSWIRE) — BexBack Exchange has launched an aggressive new promotion to empower both new and seasoned crypto traders: a $50 welcome bonus and a 100% deposit match for all new users. As the crypto market braces for another period of high volatility, BexBack is making futures trading more accessible and profitable than ever. With up to 100x leverage, zero KYC requirements, and support for over 50 digital assets, the platform provides an ideal environment for those seeking to capitalize on market swings without large upfront capital. Advantages of 100x Leverage Crypto Futures Amplified Profits: Control large positions with a small amount of capital, capturing more profits from market fluctuations. Low Capital Requirement: Participate in high-value trades with minimal investment, lowering the entry barrier. Increased Market Opportunities: Profit quickly from price fluctuations, especially in volatile markets. High Capital Efficiency: Leverage enables better use of your capital, expanding your investment potential. Profit from Both Up and Down Markets: Adapt to any market conditions, with opportunities to profit whether the market goes up or down. What Is 100x Leverage and How Does It Work? Simply put, 100x leverage allows you to open larger trading positions with less capital. For example: Suppose the Bitcoin price is $100,000 that day, and you open a long contract with 1 BTC. After using 100x leverage, the transaction amount is equivalent to 100 BTC. One day later, if the price rises to $105,000, your profit will be (105,000 – 100,000) * 100 BTC / 100,000 = 5 BTC, a yield of up to 500%. With BexBack's deposit bonus BexBack offers a 100% deposit bonus . If the initial investment is 2 BTC, the profit will increase to 10 BTC, and the return on investment will double to 1000%. Note: Although leveraged trading can magnify profits, you also need to be wary of liquidation risks. How Does the 100% Deposit Bonus Work? The deposit bonus from BexBack cannot be directly withdrawn but can be used to open larger positions and increase potential profits. Additionally, during significant market fluctuations, the bonus can serve as extra margin, effectively reducing the risk of liquidation. About BexBack? BexBack is a leading cryptocurrency derivatives platform offering up to 100x leverage on futures contracts for BTC, ETH, ADA, SOL, XRP, and over 50 other digital assets. Headquartered in Singapore, the platform also operates offices in Hong Kong, Japan, the United States, the United Kingdom, and Argentina. Like many top-tier exchanges, BexBack holds a U.S. MSB (Money Services Business) license and is trusted by more than 500,000 traders worldwide. The platform accepts users from the United States, Canada, and Europe, with zero deposit fees and 24/7 multilingual customer support, delivering a secure, efficient, and user-friendly trading experience. Why recommend BexBack? No KYC Required: Start trading immediately without complex identity verification. 100% Deposit Bonus : Double your funds, double your profits. High-Leverage Trading: Offers up to 100x leverage, maximizing investors' capital efficiency. Demo Account : Comes with 10 BTC in virtual funds, ideal for beginners to practice risk-free trading. Comprehensive Trading Options: Feature-rich trading available via Web and mobile applications. Convenient Operation: No slippage, no spread, and fast, precise trade execution. Global User Support: Enjoy 24/7 customer service, no matter where you are. Lucrative Affiliate Rewards: Earn up to 50% commission, perfect for promoters. Take Action Now—Don't Miss Another Opportunity! If you missed the previous crypto bull run, this could be your chance. With BexBack's 100x leverage and 100% deposit bonus and $50 bonus for new users (complete one trade within one week of registration), you can be a winner in the new bull run. Sign Up Now on BexBack — Break the 100x Leverage and KYC Barriers, Get Double Deposit Bonus and $50 Welcome Bonus Instantly Website: Contact: [email protected] Contact:Amanda [email protected] Disclaimer: This content is provided by BexBack. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be guaranteed. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page. Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. Photos accompanying this announcement are available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
a day ago
- Yahoo
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
– Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – – All 12 patients with at least one year of follow-up who received a full dose of zimislecel as a single infusion achieved ADA-recommended target HbA1c levels <7% and >70% time-in-range (70-180 mg/dL), and 10/12 patients were insulin free – – Data presented at ADA simultaneously published in the New England Journal of Medicine – – Vertex to host investor webcast tonight, June 20, 2025, at 7:15 p.m. CT / 8:15 p.m. ET – BOSTON, June 20, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American Diabetes Association (ADA) annual conference in Chicago as part of the symposium, "Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy," from 6:15-6:30 p.m. CT (abstract 2025-A-1921) and published online by the New England Journal of Medicine. The data are from 12 patients who received the full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. Results from the study to date continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit with longer follow-up. All 12 participants: Demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up. Achieved the ADA targets of HbA1c <7% and time in range of >70%. Were free of SHEs from day 90 onwards. Had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%). 10/12 (83%) no longer required exogenous insulin at Month 12. Achieved the Phase 1/2 primary endpoint of elimination of SHEs with HbA1c <7%. Zimislecel continues to be generally well tolerated. Most adverse events (AEs) were mild or moderate, and there were no serious AEs related to zimislecel treatment. As previously reported, two patient deaths occurred, both unrelated to treatment with zimislecel. The safety profile is generally consistent with the immunosuppressive regimen used in the study, the infusion procedure, and complications from long-standing diabetes. "These data on the first fully differentiated, stem cell-derived, off-the-shelf islet cell therapy continue to be unprecedented. The magnitude, consistency and durability of the results from all 12 patients with more than one year of follow-up reinforce the transformative potential of zimislecel for people living with T1D complicated by severe hypoglycemia," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. "We are excited to complete enrollment and dosing in the Phase 1/2/3 Program and look forward to potential regulatory submissions next year." "It's remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control by both HbA1c and time in range as well as elimination of severe hypoglycemic events," said Michael R. Rickels, M.D., M.S., Medical Director, Pancreatic Islet Cell Transplant Program, Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Presenting Author and Steering Committee Co-Chair for the zimislecel clinical program, and author on the New England Journal of Medicine paper. "As I think about my patients and the unmet need in the type 1 diabetes community, the results we've seen so far for restoring endogenous insulin secretion with a stem cell-derived islet therapy bring me hope and confidence for a transformative treatment option for individuals with type 1 diabetes in the not-so-distant future." About Type 1 DiabetesT1D results from the autoimmune destruction of insulin-producing beta cells in pancreatic islets. Insulin deficiency results in hyperglycemia and can lead to acute life-threatening complications such as diabetic ketoacidosis. People with T1D are reliant on lifelong treatment with exogenous insulin that requires careful monitoring of blood glucose levels. Even with the availability of advanced exogenous insulin delivery and glucose monitoring systems, people with T1D can have periods of very low and very high blood sugar levels. Exogenous insulin has a narrow therapeutic range and carries an inherent risk of causing low blood sugar levels or hypoglycemic events, which can potentially result in arrhythmias, seizures, coma and even death. Due to the limitations and complexities of exogenous insulin treatment, it can be difficult for people with T1D to achieve and maintain good glucose control. Exposure to prolonged periods of high blood glucose levels, or hyperglycemia, can lead to long-term complications such as nerve damage, kidney disease/failure, eye disease (including vision loss), cardiovascular disease, stroke and even death. HbA1c is a measure of average blood glucose over the most recent ~2-3 months, and the consensus guidance is to maintain an HbA1c of <7% to reduce the risk of long-term complications; only ~1 in 4 people with T1D globally meet this clinical target. Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There is no cure for T1D. About ZimislecelZimislecel (VX-880) is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. Zimislecel is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. Zimislecel has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. Zimislecel is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The zimislecel trial has expanded to additional sites that are currently active and enrolling in the U.S., Canada and Europe. Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Zimislecel is investigational and has not been approved by health authorities globally. About VertexVertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Carmen Bozic, M.D., and Michael R. Rickels, M.D., M.S., in this press release, (ii) plans, expectations for, and the potential benefits of zimislecel, (iii) expectations for the Phase 1/2/3 clinical trial for zimislecel, including expectations for the trial to complete enrollment and dosing, and (iv) plans for potential regulatory submissions next year. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, that timelines for regulatory submissions may be longer than anticipated, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Investor Event and Webcast Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex's website at An archived webcast will be available on the company's website. View source version on Contacts Vertex Pharmaceuticals IncorporatedInvestors: InvestorInfo@ Media: mediainfo@ orInternational: +44 20 3204 5275
Business Wire
a day ago
- Business Wire
Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions
LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited ('Verdiva' or 'the Company') a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and cardiometabolic disorders, will present new data showcasing the once-weekly potential of Verdiva's investigational oral GLP-1RA and amylin analog peptide candidates at the American Diabetes Association (ADA) 85th Scientific Sessions. 'These presentations underscore the potential value of our compounds as the only once-weekly oral amylin and oral GLP-1 receptor agonist (RA) candidates known to be advancing into clinical studies," said Dr. Mohamed Eid, CMO, Verdiva Bio Share 'Our first data presentation as Verdiva Bio at the prestigious ADA meeting marks a key milestone for our team. These presentations underscore the potential value of our compounds as the only once-weekly oral amylin and oral GLP-1 receptor agonist (RA) candidates known to be advancing into clinical studies,' stated Dr. Mohamed Eid, CMO at Verdiva. 'The early clinical and preclinical data not only show the potential of these compounds individually, but also the additive effect they may have in combination, highlighting the flexibility of our modular portfolio approach. At Verdiva Bio, we are committed to developing convenient, patient-friendly and commercially scalable therapeutic options for obesity, cardiometabolic disorders and related complications. We're excited about the potential of our once-weekly oral peptide candidates to help address this global health challenge.' VRB-101: An investigational once-weekly oral GLP-1 analog This presentation highlights new clinical pharmacokinetic data for VRB-101, an investigational, once-weekly, cAMP-biased oral GLP-1RA formulated with Verdiva's clinically validated, proprietary oral delivery technology T2026. Phase 1 results demonstrated that oral VRB-101 achieved drug levels comparable to, or exceeding, those of currently available once-weekly injectable GLP-1RA therapies. These findings support continued investigation of VRB-101 as a potential once-weekly, scalable oral therapeutic option for both weight reduction and long-term weight maintenance, with the potential to exert potent weight reduction and may improve adherence via a more patient-friendly dosing regimen. Poster Presentation #069 Title: VRB-101 is a potent oral GLP-1 tablet with once-weekly dosing potential Date/Time: June 21, 2025, 12:30–1:30 p.m. Central Time Location: Poster Hall (Hall F1) 068, McCormick Place Convention Center VRB-103: Efficacy of novel once-weekly oral amylin analog as a monotherapy, and in combination with VRB-101 in vivo A second presentation will share novel preclinical data on VRB-103, an investigational potentially once-weekly oral amylin analog, tested alone and in combination with VRB-101. In preclinical models, the rationally designed peptide combination showed an additive effect on body weight reduction. Additionally, co-formulation of these peptides in a single tablet with T2026 maintained comparable plasma exposure for both compounds. These data support continued development of VRB-103 as both a monotherapy and in combination with VRB-101. Poster Presentation #068 Title: Efficacy of a novel oral amylin analog and the development of an oral GLP-1/amylin co-formulated tablet to produce high in vivo plasma exposures Date/Time: June 21, 2025, 12:30–1:30 p.m. Central Time Location: Poster Hall (Hall F1) 068, McCormick Place Convention Center About Verdiva Bio Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva's most advanced product candidate is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated potential efficacy in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing potential. The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy and improved tolerability. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide. For more information, please visit
